Association between HLA-DQA1/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment.
Adult
Aged
Carcinoma, Hepatocellular
/ etiology
Female
Fibrosis
Genome-Wide Association Study
Genotype
Guanine
/ analogs & derivatives
HLA-DQ alpha-Chains
/ genetics
HLA-DRB1 Chains
/ genetics
Hepatitis B, Chronic
/ complications
Humans
Liver
/ pathology
Liver Neoplasms
/ etiology
Male
Middle Aged
Multivariate Analysis
Polymorphism, Single Nucleotide
/ genetics
Risk Factors
Young Adult
hepatocellular carcinoma
human leukocyte antigen
liver cirrhosis
single-nucleotide polymorphism
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
21
04
2018
revised:
14
08
2018
accepted:
16
08
2018
pubmed:
31
8
2018
medline:
27
11
2019
entrez:
31
8
2018
Statut:
ppublish
Résumé
It remains unclear whether there is an association between single-nucleotide polymorphisms (SNPs) and development of hepatocellular carcinoma (HCC) during entecavir (ETV) treatment in nucleos(t)ide analog-naïve patients with chronic hepatitis B virus infection. We investigated the risk factors for HCC, especially host factors, during ETV treatment. A total of 127 Japanese patients undergoing ETV treatment were enrolled in this study. Univariate and multivariate analyses for clinical factors, hepatic fibrosis markers, and SNPs associated with HCC development were analyzed. A total of 10 patients developed HCC during the follow-up period (median duration, 3.3 years). The 3-, 5-, and 7-year cumulative rates of HCC development were 4.8%, 10.6%, and 13.6%, respectively. Liver fibrosis (cirrhosis; P = 0.0005), age (≥ 49 years; P = 0.0048), platelet count (≤ 115 × 10/mm Our findings suggested that patients with AA genotype in the HLA-DQA1/DRB1 gene or cirrhosis should be carefully followed up as a population potentially at higher risk of HCC during ETV treatment.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
It remains unclear whether there is an association between single-nucleotide polymorphisms (SNPs) and development of hepatocellular carcinoma (HCC) during entecavir (ETV) treatment in nucleos(t)ide analog-naïve patients with chronic hepatitis B virus infection. We investigated the risk factors for HCC, especially host factors, during ETV treatment.
METHODS
METHODS
A total of 127 Japanese patients undergoing ETV treatment were enrolled in this study. Univariate and multivariate analyses for clinical factors, hepatic fibrosis markers, and SNPs associated with HCC development were analyzed.
RESULTS
RESULTS
A total of 10 patients developed HCC during the follow-up period (median duration, 3.3 years). The 3-, 5-, and 7-year cumulative rates of HCC development were 4.8%, 10.6%, and 13.6%, respectively. Liver fibrosis (cirrhosis; P = 0.0005), age (≥ 49 years; P = 0.0048), platelet count (≤ 115 × 10/mm
CONCLUSIONS
CONCLUSIONS
Our findings suggested that patients with AA genotype in the HLA-DQA1/DRB1 gene or cirrhosis should be carefully followed up as a population potentially at higher risk of HCC during ETV treatment.
Substances chimiques
HLA-DQ alpha-Chains
0
HLA-DQA1 antigen
0
HLA-DRB1 Chains
0
entecavir
5968Y6H45M
Guanine
5Z93L87A1R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
937-946Subventions
Organisme : Japan Society for the Promotion of Science
ID : 15K19345
Organisme : JSPS KAKENHI
ID : JP 15K19345
Informations de copyright
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.